Markets:

Overview

News

Currencies

International

Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

93.04 +1.52 (+1.66%)

Streaming Delayed Price Updated: 11:52 AM EST, Nov 25, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

73 74 Next >

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZeneca

February 19, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

What's a Good Price for AstraZeneca Stock? ↗

February 19, 2025

Via The Motley Fool

10 Health Care Stocks Whale Activity In Today's Session ↗

February 18, 2025

Via Benzinga

How Is The Market Feeling About AstraZeneca? ↗

February 17, 2025

Via Benzinga

2 Healthcare Stocks That Tumbled in 2024...but Could See an Impressive Comeback in 2025 ↗

February 15, 2025

Via The Motley Fool

Is NASDAQ:AZN suited for quality investing? ↗

February 14, 2025

A fundamental analysis of (NASDAQ:AZN): Is ASTRAZENECA PLC-SPONS ADR (NASDAQ:AZN) a Strong Candidate for Quality Investing?

Via Chartmill

Why AstraZeneca Topped the Market on Thursday ↗

February 06, 2025

Via The Motley Fool

AstraZeneca Unusual Options Activity ↗

February 06, 2025

Via Benzinga

AstraZeneca's Imfinzi Perioperative Regimen Shows Improved Survival Outcomes In Bladder Cancer Patients ↗

February 14, 2025

AstraZeneca's Imfinzi perioperative regimen improved survival outcomes in muscle-invasive bladder cancer, with FDA Priority Review expected in Q2 2025.

Via Benzinga

IMFINZI® (durvalumab) perioperative regimen improved event-free survival and overall survival across muscle-invasive bladder cancer patients regardless of complete pathology response status in post-hoc exploratory analysis of NIAGARA Phase III trial

February 14, 2025

From AstraZeneca

Via Business Wire

Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday? ↗

February 13, 2025

Ascendis Pharma beat Q4 earnings and revenue estimates, driven by a $100M Novo Nordisk deal and Yorvipath's EU launch. Goldman Sachs raised its price target.

Via Benzinga

This AstraZeneca Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday ↗

February 13, 2025

Via Benzinga

Earnings Scheduled For February 6, 2025 ↗

February 06, 2025

Via Benzinga

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZeneca

February 12, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

Trade Desk, Leidos, Devon Energy And A Major Health Care Stock On CNBC's 'Final Trades' ↗

February 12, 2025

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

February 11, 2025

Via Benzinga

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against IIPR, AstraZeneca, FTAI, and Revance and Encourages Investors to Contact the Firm

February 10, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Lowey Dannenberg Notifies AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $200,000 in Losses to Contact the Firm

February 07, 2025

From Lowey Dannenberg, P.C.

Via GlobeNewswire

AstraZeneca Plc (AZN) Q4 2024 Earnings Call Transcript ↗

February 06, 2025

AZN earnings call for the period ending December 31, 2024.

Via The Motley Fool

Topics Earnings

AstraZeneca Bounds Higher On Fourth-Quarter Beat, Upbeat Guidance ↗

February 06, 2025

AstraZeneca stock rose early Thursday after the drugmaker beat fourth-quarter earnings views and delivered upbeat guidance.

Via Investor's Business Daily

AstraZeneca Q4 Earnings: Revenue And EPS Beat On Higher Cancer And Respiratory Drug Sales, Faces $4.5 Million Potential Fine In China ↗

February 06, 2025

AstraZeneca's Q4 revenue beat estimates at $14.89 billion, with strong oncology sales. China sales dipped 1%, while FY25 guidance forecasts solid growth.

Via Benzinga

Arcutis Soared In 2024, Blazing Trails In Dermatology. Why Its CEO Eyes Bigger Gains. ↗

February 06, 2025

The company won three FDA approvals over the past two years. Now, it's angling for two new approvals in 2025.

Via Investor's Business Daily

AstraZeneca’s Full Year and Q4 2024 results

February 06, 2025

From AstraZeneca

Via Business Wire

February 04, 2025

From Lowey Dannenberg, P.C.

Via GlobeNewswire

Q4 Earnings Scorecard & Analyst Reports For Alphabet, Blackstone & KLA ↗

February 03, 2025

Today's Research Daily features a real-time scorecard of the Q4 earnings season and new research reports on 16 major stocks, including Alphabet Inc., Blackstone Inc., and KLA Corporation, as well as a...

Via Talk Markets

Topics Stocks / Equities

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioAge, AstraZeneca, FTAI, and Revance and Encourages Investors to Contact the Firm

February 03, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

AstraZeneca Blames 'Toxic' Climate As It Walks Away from Over $550 Million UK Vaccine Plant ↗

February 03, 2025

AstraZeneca scrapped plans for a £450 million UK vaccine plant after rejecting a £78 million government offer, citing concerns over NHS drug pricing and industry tensions.

Via Benzinga

ROSEN, THE FIRST FILING FIRM, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AZN

February 02, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

January 31, 2025

From Lowey Dannenberg, P.C.

Via GlobeNewswire

ROSEN, THE FIRST FILING FIRM, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AZN

January 30, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

73 74 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.